Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S, dated January 12, 2026, provides a business and strategic roadmap update. The report outlines planned corporate milestones for 2026, focusing on the commercial expansion of approved TransCon therapies and clinical progress for pipeline candidates.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period. The only financial metric disclosed is the authorization of a new $120 million Share Repurchase Program. The timing and amount of repurchases will depend on market conditions and are not guaranteed.
Material Changes and Clinical Milestones
- TransCon PTH (YORVIPATH): Achieved over 5,300 unique U.S. patient enrollments and nearly 2,400 unique prescribing providers by year-end. Commercial availability expanded to over 30 countries outside the U.S., with 10 additional launches anticipated in 2026. A once-weekly dosing profile was confirmed for stable patients.
- TransCon hGH (SKYTROFA): Received FDA approval for adult growth hormone deficiency (GHD) in July 2025. Initiated a Phase 3 basket trial for additional indications including idiopathic short stature and Turner syndrome.
- TransCon CNP (navepegritide): The U.S. PDUFA goal date for pediatric achondroplasia is set for February 28, 2026. An MAA was submitted to the EMA in October 2025, with a decision expected in Q4 2026.
- Combination Therapy (TransCon CNP + hGH): Week 52 topline results from the Phase 2 COACH Trial (announced January 8, 2026) showed annualized growth velocity exceeding the 97th percentile. A Phase 3 protocol was submitted to the FDA in Q4 2025.
- TransCon IL-2 β/γ: Median overall survival data for the IL-Believe Trial in ovarian cancer is expected in Q2 2026.
Guidance, Outlook, and Strategic Updates
Management highlighted several strategic collaborations and regulatory timelines:
- Novo Nordisk: The lead program, TransCon semaglutide for obesity, remains on track to enter the clinic as anticipated.
- Eyconis, Inc.: Ascendis holds a 41% equity stake. The lead ophthalmology program (TransCon aVEGF) is expected to enter the clinic in 2026.
- VISEN Pharmaceuticals: Ascendis holds a 39% stake. The NMPA in China accepted the BLA for TransCon hGH in March 2024, with an approval decision anticipated in Q1 2026.
- Teijin Limited: YORVIPATH received MAA approval in Japan in August 2025.
Risks and Contingencies: The filing includes extensive forward-looking statements warning of risks related to regulatory approvals, clinical trial outcomes, manufacturing dependencies, reimbursement challenges, and geopolitical factors. Actual results may differ materially from projections.
Investor Verification Checklist
- Verify the February 28, 2026, PDUFA decision date for TransCon CNP (navepegritide) in the U.S.
- Monitor the Q1 2026 NMPA approval decision for TransCon hGH in China.
- Review the Q2 2026 release of Week 78 COACH data and median overall survival data from the IL-Believe Trial.
- Track the execution and volume of the newly authorized $120 million share repurchase program.
- Confirm the timeline for the clinic entry of TransCon semaglutide (Novo Nordisk collaboration) and TransCon aVEGF (Eyconis collaboration).